Basilea Pharmaceutica (XSWX:BSLN) YoY EPS Growth: 77.34% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
60 GF Score
Price CHF69.00
GF Value CHF57.85
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica YoY EPS Growth?

Basilea Pharmaceutica XSWX:BSLN 60 YoY EPS Growth is 77.34% as of Jun. 2026. GuruFocus rates XSWX:BSLN with a GF Score™ of 60/100 and a GF Value™ of CHF57.85 (Modestly Overvalued). The stock has 5 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Basilea Pharmaceutica's YoY EPS Growth for the quarter that ended in Jun. 2026 was 77.34%.

Basilea Pharmaceutica's Earnings per Share (Diluted) for the six months ended in Jun. 2026 was CHF2.02.

Basilea Pharmaceutica YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica YoY EPS Growth Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.16 273.91 -15.37 576.73 -46.05

Basilea Pharmaceutica Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.17 336.29 -29.27 -55.39 77.34
XSWX:BSLN
60GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Basilea Pharmaceutica's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(3.1422-5.8246)/ | 5.8246 |
=-46.05 %

Basilea Pharmaceutica's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(2.0236-1.1411)/ | 1.1411 |
=77.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 77.34% mean?
Basilea Pharmaceutica (XSWX:BSLN) has a YoY EPS Growth of 77.34% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's YoY EPS Growth too high?
Basilea Pharmaceutica's current YoY EPS Growth is 77.34%. Overall, Basilea Pharmaceutica has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's YoY EPS Growth compare to VRTX and REGN?
Basilea Pharmaceutica's YoY EPS Growth of 77.34% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current YoY EPS Growth is 77.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF57.85, compared to a current price of CHF69.00 — trading 19.3% above its estimated fair value. The current YoY EPS Growth is 77.34%. Basilea Pharmaceutica's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current YoY EPS Growth is 77.34% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be overvalued. The current stock price of CHF69.00 is trading 19.3% above its estimated GF Value™ of CHF57.85. GuruFocus considers Basilea Pharmaceutica to be Modestly Overvalued.

Key valuation signals for XSWX:BSLN:

  • YoY EPS Growth: 77.34%
  • GF Value™: CHF57.85 vs. price of CHF69.00 (19.3% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
60GF Score

Get the complete analysis for XSWX:BSLN

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF69.00
Price
CHF57.85
GF Value